In the pharmaceutical industry, companies often rely on raising prices on existing drugs to meet earnings targets. Lilly is doing the opposite. During the third quarter, the company’s revenue growth was driven by a 62% increase in sales volume, while realized prices for its products decreased by approximately 10%.The primary driver of Lilly’s trillion-dollar valuation is found in its third quarter 2025 earnings results. Total revenue reached $17.6 billion, a 54% increase from the same period the previous ye ...